AOD9604, by contrast, is not FDAapproved as an obesity medication, and while safety data are reassuring, its use for weight loss remains offlabel with mixed evidence for effectiveness
There is no strong evidence that it causes hypothyroidism, but it carries a warning about rare thyroid C-cell tumors seen in animal studies
The symptoms may include: headaches dizziness weakness/lack of energy brain fog joint pain, longer recovery time after workouts rashes dry skin sleep disorders depression frequent colds onset of a more serious health condition Healthy people may not notice instantaneous results when boosting glutathione levels
Improving diet, increasing fiber and fermented foods, and avoiding processed ingredients are also critical
Publication Date: 07 February 2025 Glucagon-like peptide receptor agonists (GLP-1RAs) and dual mechanism glucose-dependent insulinotropic polypeptide/glucagon-like peptide receptor agonists (GIP/GLP-1RAs) are effective treatments for weight loss and diabetes management
